ReviewTouchREVIEWS in endocrinology2023
Polycystic Ovary Syndrome as Metabolic Disease: New Insights on Insulin Resistance.
Review in TouchREVIEWS in endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Review
- Advances in the Study of Endometrial Receptivity and Glucose Metabolism Mechanisms in Insulin Resistance.Endocrinology, diabetes & metabolism · 2026Review
- Synergistic modulation of insulin resistance and ovarian oxidative stress by alpha-lipoic acid and vitamin D in an experimental rat model of polycystic ovary syndrome.Scientific reports · 2026Article
- Dysglycemia and Cardiometabolic Risk: Pathophysiological Rationale and the Emerging Role of Nutraceuticals in Integrated Prevention.Nutrients · 2026Review
- Comparison of glucolipid metabolic profile, thyroid hormone levels, and reproductive endocrine function in polycystic ovary syndrome patients with/without metabolic syndrome.American journal of translational research · 2026Article
- Interplay of Mitochondrial Dynamics, Nutrition, and Vitamins: Evidence From Experimental and Human Studies With Implications for Women's Health.Oxidative medicine and cellular longevity · 2026Review
- Endocrine Disorders and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Narrative Review.Biomedicines · 2025Review
- Polycystic ovarian syndrome a risk factor for non-communicable diseases: insights into recent research and prevention approaches.Journal of ovarian research · 2025Review
- Therapeutic efficacy of Rosa damascena Mill. on oxidative stress parameters and cyclooxygenase-2 gene expression in estradiol valerate-induced polycystic ovarian syndrome in Wistar rats.Scientific reports · 2025Article
- PCOS and Obesity: Contraception Challenges.Open access journal of contraception · 2025Review
- The regulatory effects of realgar and cinnabar on glucose metabolism in mice.Frontiers in endocrinology · 2025Article
- Insulin resistance, metabolic syndrome and polycystic ovaries: an intriguing conundrum.Frontiers in endocrinology · 2025Review
- Combined metformin and exenatide versus only metformin treatments in polycystic ovary syndrome with abdominal obesity and network pharmacology of gene expression: evidence from a randomized clinical trial.Therapeutic advances in endocrinology and metabolism · 2025Article
- Polycystic ovary syndrome and organochlorine pesticides: exploring potential links and mechanisms.Frontiers in reproductive health · 2025Review
- High Fat Diet and Polycystic Ovary Syndrome (PCOS) in Adolescence: An Overview of Nutritional Strategies.Nutrients · 2024Review
- Mitochondrial Dysfunction in PCOS: Insights into Reproductive Organ Pathophysiology.International journal of molecular sciences · 2023Review
- Low-Calorie Ketogenic Diet: Potential Application in the Treatment of Polycystic Ovary Syndrome in Adolescents.Nutrients · 2023Review
- Glycemic Index and Glycemic Load Estimates in the Dietary Approach of Polycystic Ovary Syndrome.Nutrients · 2023Review
- Controlled attenuation parameters to assess liver steatosis in obese patients with polycystic ovary syndrome.Frontiers in endocrinology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polycystic ovary syndrome (PCOS) is a very frequent disease that affects reproductive ability and menstrual regularity. Other than the criteria established at the Rotterdam consensus, in these last few years a new issue, insulin resistance, has been found frequently, and at a very high grade, in patients with PCOS. Insulin resistance occurs for several factors, such as overweight and obesity, but it is now clear that it occurs in patients with PCOS with normal weight, thus supporting the hypothesis that insulin resistance is independent of body weight. Evidence shows that a complex pathophysiological situation occurs that impairs post-receptor insulin signalling, especially in patients with PCOS and familial diabetes. In addition, patients with PCOS have a high incidence of non-alcoholic fatty liver disease related to the hyperinsulinaemia. This narrative review focuses on the recent new insights about insulin resistance in patients with PCOS, to better understand the metabolic impairment accounting for most of the clinical signs/symptoms of PCOS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.